3 days agoAnavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Nov 26Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Nov 25Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Oct 31Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 17Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Sep 3Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 1Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Jul 30Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Jul 28Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
